The Emergence of Universal Immune Receptor T Cell Therapy for Cancer

Chimeric antigen receptor (CAR) T cells have shown great success in the treatment of CD19+ hematological malignancies, leading to their recent approval by the FDA as a new cancer treatment modality. However, their broad use is limited since a CAR targets a single tumor associated antigen (TAA), whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Minutolo, Nicholas G., Hollander, Erin E., Powell, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448045/
https://www.ncbi.nlm.nih.gov/pubmed/30984613
http://dx.doi.org/10.3389/fonc.2019.00176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448045/
https://www.ncbi.nlm.nih.gov/pubmed/30984613
http://dx.doi.org/10.3389/fonc.2019.00176

Ejemplares similares